中山大学“百人计划”
引进人才
作者:人事科   发布时间:2016-07-26 点击数:8243
<< 更多 >>
刘强

基本情况

姓名:刘强       性别:男

职称:教授、主任医师、研究员     

行政职务:乳腺肿瘤医学部副主任、对外交流与拓展办公室主任

学科专业:乳腺外科   导师资格:博士研究生导师

研究方向:乳腺肿瘤   电子邮箱:victorlq@hotmail.com

个人简介

刘强,教授、主任医师、研究员,外科学博士,1996年毕业于中南大学湘雅医学院七年制临床医学专业,获外科学硕士学位,毕业后在湘雅医院任普外科医生。2000至2004 年获新加坡全额奖学金资助于新加坡国立大学医学院外科攻读并获得博士学位。随后分别在新加坡国立大学肿瘤研究所及美国哈佛大学医学院Dana Farber癌症研究所任博士后研究员,2008年晋升为哈佛大学医学院Dana Farber癌症研究所及Brigham and Women医院肿瘤科讲师(Instructor in Medicine)。2011年以中山大学“百人计划”人才引进回国。现为中山大学孙逸纪念医院乳腺外科博士研究生导师,乳腺肿瘤医学部副主任,对外交流与拓展办公室主任。

回国后主要从事乳腺肿瘤临床及科研工作,对乳腺肿瘤的发生发展、肿瘤微环境、侵袭转移及治疗耐药等有较深入的研究。主要研究方向如下:

1)非编码RNA在乳腺肿瘤发生发展中的作用及机制研究。

2)肿瘤耐药的机制研究。

3)肿瘤微环境在乳腺癌发生发展中的作用。

共发表SCI论文三十余篇,包括以第一或通讯作者(含共同)在《Cancer Cell》、《Nature Communication》和《Cancer Research》等国际著名学术期刊发表的论文,影响因子共计275.3,其中第一作者(含共同)论文6篇,影响因子达63.7,通讯作者(含共同)论文8篇,影响因子达52.1。先后参与了三本英文肿瘤学专著的写作及以副主编组织编写了《乳腺癌保乳治疗》。回国以来,先后主持中国国家自然科学基金面上项目3项,获得国家重点基础研究计划(973计划)资助1项(课题组组长),并获得广东省国际合作重点项目1项。多次应邀在国内外大型学术会议上演讲,如2014年在ASCO-CSCO Joint Symposium上做题为“Targeted therapy in translational medicine”的演讲和2015年CSCO乳腺癌高峰会做题为“转化医学对乳腺癌未来治疗的影响”的演讲。

重要学术研究成果与贡献

一)基金

1.课题组组长,国家重点基础研究计划(973计划),SQ2015CB050449,2015-2019,炎-癌生物信号交互调控癌进展及阻抑治疗分子机制,420万。

2.负责人,中国国家自然科学基金面上项目, 81472467, 2015-2018,肿瘤相关巨噬细胞对乳腺癌干细胞化疗耐药的调控机制研究,80万。

3.负责人,中国国家自然科学基金面上项目, 81272894, 2013-2016, 长非编码RNA在乳腺癌Cyclin D1相关内分泌治疗耐药中的机制研究,60万。

4.负责人,中国国家自然科学基金面上项目,81072178,2011-2013,Cyclin D1-C/EBPβ信号通道在乳腺癌变中的靶细胞及其与Tamoxifen耐药的关系,35万。

5.负责人,广东省科技计划项目,乳腺肿瘤干细胞的雌激素反应网络研究,2015-2017,50万。 

二)发表论文

通讯作者(含共同)论文

1.   Gong C, Qu S, Lv XB, Liu B, Tan W, Nie Y, Su F, Liu Q*, Yao H*, Song E*. BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10. Nat Commun, 2014, 5:5406. (* co-corresponding author) (IF=11.329)

2.   Gong C, Nie Y, Qu S, Liao JY, Cui X, Yao H, Zeng Y, Su F, Song E*, Liu Q*. miR-21 Induces Myofibroblast Differentiation and Promotes the Malignant Progression of Breast Phyllodes Tumors. Cancer Res. 2014, 74(16):4341-4352. (* co-corresponding author) (IF=8.556)

3.   Gong C, Qu S, Liu B, Pan S, Jiao Y, Nie Y, Su F, Liu Q*, Song E*. MiR-106b expression determines the proliferation paradox of TGF-β in breast cancer cells. Oncogene, 2015, 34(1):84-93.. (* co-corresponding author) (IF=7.932)

4.   Tang W, Yu F, Yao H, Cui X, Jiao Y, Lin L, Chen J, Yin D, Song E*, Liu Q*. miR-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene. 2014, 33(20):2629-38. (* co-corresponding author) (IF=7.932)

5.    Chu J, Zhu Y, Liu Y, Sun L, Lv X, Wu Y, Hu P, Su F, Gong C, Song E, Liu B*, Liu Q*. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter. Oncotarget. 2015, 6(31):31944-57. (*, co-corresponding author) ( IF=5.008)

6.   Liu J, Guo H, Mao K, Zhang K,Deng H, Liu Q. Impact of estrogen receptor-β expression on breast cancer prognosis: a meta-analysis. Breast Cancer Res Treat. 2016, 156(1):149-62.(IF= 4.085)

7.    Liu J, Jiang W, Mao K, An Y, Su F, Kim BYS, Liu Q*, Jacobs LK*. Elevated Risks of Subsequent Endometrial Cancer Development among Breast Cancer Survivors with Different Hormone Receptor Status: A SEER Analysis. Breast Cancer Res Treat, 2015, 150(2):439-45. (* co-corresponding author) (IF= 4.085)

8.    Li S, Liu J, Yang Y, Zeng Y, Deng H, Jia H, Li Q, Feng H, Li Y, Song E, Liu Q*, Su F*. Impact of atypical hyperplasia at margins of breast-conserving surgery on the recurrence of breast cancer. J Cancer Res Clin Oncol. 2014, 140(4):599-605 (* co-corresponding author)( IF= 3.141)

第一作者(含共同)论文

9.    Liu B#, Sun L#, Liu Q#, Gong C#, Yao Y, Lv X, Lin L, Yao H, Su F, Li D, Zeng M, Song E. A Cytoplasmic NFkB Interacting Long Noncoding RNA Blocks IkB Phosphorylation and Suppresses Breast Cancer Metastasis. Cancer Cell, 2015, 27(3):370-81, the cover story of the issue. (# co-first author) (IF= 23.214)

10.  Su S#, Liu Q#, Chen J, Chen J, Chen F, He C, Wu W, Lin L,Li H, Huang D, Huang W, Yu F, Zhang J, Cui X, Zheng F, Yao H, Su F, Song E. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell. 2014, 25(5):605-620 (#, co-first author) (IF= 23.214)

11.  Liu Q, Teh M, Ito K, Shah N, Ito Y, Yeoh KG. CDX2 expression is progressively decreased in human gastric intestinal metaplasia, dysplasia and cancer. Mod Pathol, 2007, 20(12):1286-1297(IF=5.485)

12. Liu Q, Chan STF, Mahendran R. Nitric Oxide induces cyclooxygenase expression and inhibits cell growth in colon cancer cell lines. Carcinogenesis, 2003, 24(4): 637-642 (IF=4.874)

13.  Liu Q, Boudot A, Ni J, Hennessey T, Beauparlant S, Rajabi H, Zahnow CA, Ewen ME. Cyclin D1 and C/EBPβ LAP1 operate in a common pathway to promote mammary epithelial cell differentiation. Mol Cell Biol. 2014, 34(16):3168-3179. (IF=4.427)

14. Liu Q, Inoue H, Mahendran R. Transcriptional regulation of the COX-2 expression by nitric oxide in colon cancer cell lines. Oncol Rep. 2008, 19(1):269-274(IF= 2.486)

非第一/通讯作者论文

15. Chen J, Yao Y, Gong C, Yu F, Su S, Chen J, Liu B, Deng H, Wang F, Lin L, Yao H, Su F, Anderson KS, Liu Q, Ewen ME, Yao X, Song E. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 2011, 19(4):541-555. (IF= 23.214)

16. Chang TL, Ito K, Ko TK, Liu Q, Salto-Tellez M, Yeoh KG, Ito Y. Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology. 2010, 138(1):255-265 (IF=18.187)

17.Yao YD, Sun TM, Huang SY, Dou S, Lin L, Chen JN, Ruan JB, Mao CQ, Yu FY, Zeng MS, Zang JY, Liu Q, Su FX, Zhang P, Lieberman J, Wang J, Song E. Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2+ Breast Cancer Growth and Metastasis. Sci Transl Med, 2012, 18(4):130ra48. (IF=16.264)

18.  Müller CI, Luong QT, Shih LY, Jones LC, Desmond JC, Kawamata N, Tcherniantchouk O, Liu Q, Ito K, Osato M, Ito Y, Tefferi A, de Vos S, Koeffler HP. Identification of marker genes including RUNX3 (AML2) that discriminate between different myeloproliferative neoplasms and normal individuals. Leukemia. 2008, 22(9):1773-1778(IF=12.104)

19.  Su S, Zhao Q, He C, Huang D, Liu J, Chen F, Chen J, Liao JY, Cui X, Zeng Y, Yao H, Su F, Liu Q, Jiang S, Song E. miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program. Nat Commun. 2015, 6:8523. doi: 10.1038/ncomms9523. (IF=11.329)

20. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Ito Y, Sukumar S. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Research, 2006, 66(13): 6512-6520 (IF= 8.556)

21.  Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, Hiong KC, Peh BK, Han HC, Ito T, Teh M, Yeoh KG, Ito Y. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Research, 2005, 65(17): 7743-7750 (IF= 8.556)

22.  Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M, Zhang W, Chen W, Pan C, Liu Q, Song E, Li J. MiR-200b and miR-15b regulate chemotherapy-induced epithelial- mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2012, 31(4):432-445. (IF=7.932)

23.Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene. 2010, 29(29):4194-4204 (IF=7.932)

24. Su S, Wu W, He C, Liu Q, Song E. Breaking the vicious cycle between breast cancer cells and tumor-associated macrophages. Oncoimmunology. 2014, 3(8):e953418.(IF= 7.644)

25.  Liu J, Mao K, Jiang S, Jiang W, Chen K, Kim BY, Liu Q, Jacobs LK. The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB. Oncotarget. 2015 Dec 18. doi: 10.18632 /oncotarget.6664.( IF=5.008)

26.  Liu J, Chen K, Mao K, Su F, Liu Q, Jacobs LK. The prognostic value of age for invasive lobular breast cancer depending on estrogen receptor and progesterone receptor-defined subtypes: A NCDB analysis. Oncotarget. 2015 Oct 28. doi: 10.18632/oncotarget.5844. ( IF=5.008)

27.  Gong C, Liu B, Yao Y, Qu S, Luo W, Tan W, Liu Q, Yao H, Zou L, Su F, Song E. Potentiated DNA Damage Response in Circulating Breast Tumor Cells Confers Resistance to Chemotherapy. J Biol Chem. 2015, 290(24):14811-25. (IF=4.258)

28.  Zhao J, Liu J, Chen K, Li S, Wang Y, Yang Y, Deng H, Jia W, Rao N, Liu Q, Su F. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2014, 145(1):113-28. (IF= 4.085)

29.Li HY, Cui XY, Wu W, Yu FY, Yao HR, Liu Q, Chen JQ. Pyk2 and Src mediate signaling to CCL18-induced breast cancer metastasis. J Cell Biochem. 2014, 115:596-603. (IF= 3.446)

30. Liu Y, Li H, Feng J, Cui X, Huang W, Li Y, Su F, Liu Q, Zhu J, Lv X, Chen J, Huang D, Yu F. Lin28 Induces Epithelial-to-Mesenchymal Transition and Stemness via Downregulation of Let-7a in Breast Cancer Cells. PLoS One. 2013, 8(12):e83083.( IF=3.057)

31. Tang W, Zhu J, Su S, Wu W, Liu Q, Su F, Yu F. MiR-27 as a prognostic marker for breast cancer progression and patient survival. PLoS One. 2012, 7(12):e51702( IF=3.057)

32. Gong C, Yao H, Liu Q, Chen J, Shi J, Su F, Song E. Markers of tumor-initiating cells predict chemoresistance in breast cancer. PLoS One. 2010 Dec 20;5(12):e15630 ( IF=3.057)

33. Yang Y, Liu J, Gu R, Hu Y, Liu F, Yun M, Xiao Q, Wu M, Liu Q, Su F. Influence of factors on mammographic density in premenopausal Chinese women.  Eur J Cancer Prev. 2015 Jun 11.( IF=2.415)

34. Tian H, Qin W, Wu W, Guo P, Lu Y, Liu P, Liu Q, Su F. Effects of Traditional Chinese Medicine on Chemotherapy-Induced Myelosuppression and Febrile Neutropenia in Breast Cancer Patients. Evid Based Complement Alternat Med. 2015, 736197. (IF=1.931)

35. Huang D, Su S, Cui X, Shen X, Zeng Y, Wu W, Chen J, Chen F, He C, Liu J, Huang W, Liu Q, Su F, Song E, Ouyang N. Nerve fibers in breast cancer tissues indicate aggressive tumor progression. Medicine (Baltimore). 2014, 93(27):e172. (IF=1.206)

36.  Jia H, Jia W, Yang Y, Li S, Feng H, Liu J, Rao N, Jin L, Wu J, Gu R, Zhu L, Chen K, Deng H, Zeng Y, Liu Q, Song E, Su F. HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy. World J Surg Oncol. 2014, 12:289. (IF=1.286)

 

 

学术论著与教材

1)副主编,《乳腺癌保乳治疗》,人民卫生出版社,2014年8月, ISBN: 978-7-117-19295-8/ R3.19296。

2)Li Q, Liu Q (2016). Noncoding RNAs in Cancer Immunology, The Long and Short Noncoding RNAs in Cancer Biology, ISBN 978-981-10-1496-3, Springer.

3) Liu Q, Yu F, Tang W, Su S, Song E (2012). Cancer Stem Cell, Recent advances in caner research and therapy, ISBN: 978-0-123-97833-2, Elsevier INSIGHTS.

4)Yu F, Liu Q, Liu Y, Liu J and Song E (2011). Breast Cancer Stem Cells, Breast Cancer - Focusing Tumor Microenvironment, Stem cells and Metastasis, Mehmet Gunduz and Esra Gunduz (Ed.), ISBN: 978-953-307-766-6, InTech, Available from: http://www.intechopen.com/articles/show/title/breast-cancer-stem-cells-2

获奖及荣誉

1)  中山大学百人计划,2011年。          

2) 中山大学孙逸仙纪念医院杰青培育计划,2014年。

学术兼职

1)多个SCI期刊审稿人,如Gut、Molecular and Cellular Biology、Oncogene、Plos One等。

2)中国普通外科杂志编委

3)国家自然科学基金评审人

4)广东省抗癌协会乳腺癌专业委员会副主任委员兼秘书

5)广东省医学会乳腺病专业委员会常委兼秘书

6)广东省健康管理学会乳腺病分会副主任委员

 

相关文章